Patents by Inventor Michele P. Calos
Michele P. Calos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210162070Abstract: The present disclosure provides methods for altering a phenotypic characteristic of muscular dystrophy, treating muscular dystrophy, and/or alleviating a symptom of muscular dystrophy. Methods for integrating a polynucleotide sequence into the genome of a human cell are provided. The present methods result in alteration of the phenotypic characteristic of muscular dystrophy, treatment of muscular dystrophy, and/or alleviating a symptom of muscular dystrophy. Also provided are nucleic acids that include sequences for integrating a polynucleotide sequence of interest into the genome of a human cell. A transgenic human cell including site specific recombination sites is also disclosed.Type: ApplicationFiled: October 29, 2018Publication date: June 3, 2021Inventor: Michele P. Calos
-
Patent number: 8304233Abstract: The subject invention provides a unidirectional site-specific integration system for integrating a nucleic acid into the genome of a target cell. The provided system includes a site-specific integrating expression cassette (INTEC) vector, consisting of (a) a polynucleotide of interest operably linked to a promoter, (b) a single recombination site, and (c) a hybrid recombination site. In using the subject systems for site-specific integration, the INTEC vector and integrase are introduced into the target cell and the cell is maintained under conditions sufficient to provide for site-specific integration of the nucleic acid into the target cell genome via a recombination event mediated by the site-specific recombinase. Also provided are kits that include the subject systems. The subjects systems, methods and kits find use in a variety of different applications, several representative ones of which are described in detail as well.Type: GrantFiled: August 4, 2005Date of Patent: November 6, 2012Assignees: Poetic Genetics, LLC, The Board of Trustees of the Leland Stanford Junior UniversityInventor: Michele P. Calos
-
Patent number: 8227249Abstract: The present invention provides methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell, as well as, enzymes, polypeptides, and a variety of vector constructs useful therefore. In the method, a targeting construct comprises, for example, (i) a first recombination site and a polynucleotide sequence of interest, and (ii) a site-specific recombinase, which are introduced into the cell. The genome of the cell comprises a second recombination site. Recombination between the first and second recombination sites is facilitated by the site-specific recombinase. The invention describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: GrantFiled: April 2, 2008Date of Patent: July 24, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Michele P. Calos
-
Publication number: 20120141441Abstract: The present disclosure provides methods for introducing a gene encoding a muscle membrane protein into a cell isolated from a subject to generate a genetically modified cell. The genetically modified cell may be introduced back, e.g., engrafted into the subject. The isolated cell may be additionally modified by introducing into the isolated cell a gene encoding one or more reprogramming transcription factors that induce the cell to form an induced pluripotent stem cell. The genetically modified cell may be differentiated in vitro to form muscle cell precursors before engrafting into the subject. Also provided are compositions comprising autologous cells isolated from a subject which cells comprise a muscle membrane protein gene integrated into a genome attachment site in the genome of the cell. The autologous cell may be an induced pluripotent cell or a mesenchymal stem cell, such as an adipose-derived mesenchymal stem cell (AD-MSC).Type: ApplicationFiled: December 2, 2011Publication date: June 7, 2012Inventors: MICHELE P. CALOS, MARISA KAROW, CHRISTOPHER L. CHAVEZ, Alfonso P. FARRUGGIO, CHUNLI ZHAO, HASSAN CHAIB, CHRISTOPHER BJORNSON, TAWNY NEAL, JONATHAN M. GEISINGER
-
Patent number: 8101169Abstract: The present invention provides a method of treating an ocular disease in a subject. In a first step, a nucleic acid is introduced into cells or a tissue. The nucleic acid is introduced by electron avalanche transfection. With this technique, a high electric field induces a vapor bubble and plasma discharge between an electrode and the surrounding medium. The formation of a vapor bubble generates mechanical stress. Plasma discharge through the ionized vapor in the bubble enables connectivity between the electrode and the surrounding medium, so that mechanical stress and electric field are applied simultaneously, which results in permeabilization of the cells or tissue. This permeabilization in turn allows the nucleic acid to enter the cell or tissue. Cells or tissue containing the nucleic acid are then transplanted into an ocular region of the subject.Type: GrantFiled: August 15, 2006Date of Patent: January 24, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Thomas W. Chalberg, Jr., Mark Blumenkranz, Daniel V. Palanker, Alexander Vankov, Philip Huie, Jr., Michael F. Marmor, Michele P. Calos
-
Publication number: 20110177600Abstract: The subject invention provides a site-specific integration system and methods for generating eukaryotic cells lines for protein production. The provided system includes a first site-specifically integrating target vector and a second site-specifically integrating donor vector comprising a gene of interest. Also provided are mammalian cell lines produced by the subject methods and systems, as well as kits that include the subject systems.Type: ApplicationFiled: May 22, 2007Publication date: July 21, 2011Inventors: William J. Rutter, Michele P. Calos, Jimmy Z. Zhang
-
Patent number: 7842503Abstract: The present invention provides methods to site-specifically manipulate genomes by using hybrid recombinases. Hybrid recombinases comprise a modified catalytic domain from a unidirectional serine phage integrase, fused to a foreign DNA recognition domain.Type: GrantFiled: April 29, 2005Date of Patent: November 30, 2010Assignee: Poetic Genetics, LLCInventor: Michele P. Calos
-
Publication number: 20100190178Abstract: The present invention describes methods of identifying altered recombinases and compositions thereof, wherein at least one amino acid is different from a parent, wild-type recombinase and the altered recombinase has improved recombination efficiency towards wild-type and/or pseudo att site sequences relative to the parent, wild-type recombinase. The present invention also includes methods of modifying the genomes of cells using the altered recombinases, including methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell.Type: ApplicationFiled: April 9, 2010Publication date: July 29, 2010Inventors: MICHELE P. CALOS, Christopher R. Sclimenti
-
Publication number: 20090035862Abstract: The present invention provides methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell, as well as, enzymes, polypeptides, and a variety of vector constructs useful therefore. In the method, a targeting construct comprises, for example, (i) a first recombination site and a polynucleotide sequence of interest, and (ii) a site-specific recombinase, which are introduced into the cell. The genome of the cell comprises a second recombination site. Recombination between the first and second recombination sites is facilitated by the site-specific recombinase. The invention describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: ApplicationFiled: April 2, 2008Publication date: February 5, 2009Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Michele P. Calos
-
Publication number: 20080241116Abstract: The present invention provides methods to site-specifically manipulate genomes by using hybrid recombinases. Hybrid recombinases comprise a modified catalytic domain from a unidirectional serine phage integrase, fused to a foreign DNA recognition domain.Type: ApplicationFiled: April 29, 2005Publication date: October 2, 2008Inventor: Michele P. Calos
-
Patent number: 7141426Abstract: The present invention describes methods of identifying altered recombinases and compositions thereof, wherein at least one amino acid is different from a parent, wild-type recombinase and the altered recombinase has improved recombination efficiency towards wild-type and/or pseudo att site sequences relative to the parent, wild-type recombinase. The present invention also includes methods of modifying the genomes of cells using the altered recombinases, including methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell.Type: GrantFiled: April 29, 2004Date of Patent: November 28, 2006Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Michele P. Calos
-
Patent number: 6808925Abstract: The present invention describes methods of identifying altered recombinases and compositions thereof, wherein at least one amino acid is different from a parent, wild-type recombinase and the altered recombinase has improved recombination efficiency towards wild-type and/or pseudo att site sequences relative to the parent, wild-type recombinase. The present invention also includes methods of modifying the genomes of cells using the altered recombinases, including methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell.Type: GrantFiled: February 16, 2001Date of Patent: October 26, 2004Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Michele P. Calos
-
Publication number: 20040203152Abstract: The present invention provides methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell, as well as, enzymes, polypeptides, and a variety of vector constructs useful therefore. In the method, a targeting construct comprises, for example, (i) a first recombination site and a polynucleotide sequence of interest, and (ii) a site-specific recombinase, which are introduced into the cell. The genome of the cell comprises a second recombination site. Recombination between the first and second recombination sites is facilitated by the site-specific recombinase. The invention describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: ApplicationFiled: August 5, 2003Publication date: October 14, 2004Inventor: Michele P. Calos
-
Patent number: 6632672Abstract: The present invention provides methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell, as well as, enzymes, polypeptides, and a variety of vector constructs useful therefore. In the method, a targeting construct comprises, for example, (i) a first recombination site and a polynucleotide sequence of interest, and (ii) a site-specific recombinase, which are introduced into the cell. The genome of the cell comprises a second recombination site. Recombination between the first and second recombination sites is facilitated by the site-specific recombinase. The invention describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: GrantFiled: August 19, 1999Date of Patent: October 14, 2003Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Michele P. Calos
-
Publication number: 20030050258Abstract: The present invention provides methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell, as well as, enzymes, polypeptides, and a variety of vector constructs useful therefore. In the method, a targeting construct comprises, for example, (i) a first recombination site and a polynucleotide sequence of interest, and (ii) a site-specific recombinase, which are introduced into the cell. The genome of the cell comprises a second recombination site. Recombination between the first and second recombination sites is facilitated by the site-specific recombinase. The invention describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: ApplicationFiled: August 19, 1999Publication date: March 13, 2003Inventor: MICHELE P. CALOS
-
Publication number: 20020094516Abstract: The present invention describes methods of identifying altered recombinases and compositions thereof, wherein at least one amino acid is different from a parent, wild-type recombinase and the altered recombinase has improved recombination efficiency towards wild-type and/or pseudo att site sequences relative to the parent, wild-type recombinase. The present invention also includes methods of modifying the genomes of cells using the altered recombinases, including methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell.Type: ApplicationFiled: February 16, 2001Publication date: July 18, 2002Inventors: Michele P. Calos, Christopher R. Sclimenti
-
Patent number: 4753874Abstract: Mutagenic capability is determined by employing a shuttle vector having prokaryotic and eukaryotic origins, a prokaryotic marker an a gene capable of screening or selection in a prokaryote. The method involves introducing the vector into mammalian cells, exposing the cells to the candidate to be tested for mutagenicity for a time sufficient to allow lesions to occur, rescuing the vector by transforming into a prokaryotic host and screening for mutations of the gene.Type: GrantFiled: July 8, 1985Date of Patent: June 28, 1988Assignee: Board of Trustees of the Leland Stanford Junior UniversityInventor: Michele P. Calos